- Previous Close
61.80 - Open
62.40 - Bid 62.80 x 20000
- Ask 63.40 x 28000
- Day's Range
61.30 - 64.40 - 52 Week Range
37.65 - 64.40 - Volume
22,751 - Avg. Volume
6,542 - Market Cap (intraday)
1.116B - Beta (5Y Monthly) 0.83
- PE Ratio (TTM)
15.68 - EPS (TTM)
4.03 - Earnings Date Nov 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
87.00
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company's pipeline includes FYB202, a biosimilar candidate for Stelara used in the treatment of Psoriasis, Crohn's disease, and ulcerative colitis which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea that treats ophthalmology related diseases, including neovascular age-related macular degeneration that has completed Phase III clinical trials. It is also developing FYB206, a biosimilar candidate for Keytruda, for the treatment of immuno-oncology diseases; and FYB207, a SARS-CoV-2 blocker, an antiviral drug for the treatment of COVID-19. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.
www.formycon.comRecent News: FYB.DE
View MorePerformance Overview: FYB.DE
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FYB.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FYB.DE
View MoreValuation Measures
Market Cap
1.09B
Enterprise Value
1.06B
Trailing P/E
15.33
Forward P/E
120.48
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
16.99
Price/Book (mrq)
1.89
Enterprise Value/Revenue
17.47
Enterprise Value/EBITDA
16.41
Financial Highlights
Profitability and Income Statement
Profit Margin
105.09%
Return on Assets (ttm)
-1.69%
Return on Equity (ttm)
12.73%
Revenue (ttm)
60.8M
Net Income Avi to Common (ttm)
63.9M
Diluted EPS (ttm)
4.03
Balance Sheet and Cash Flow
Total Cash (mrq)
40.62M
Total Debt/Equity (mrq)
1.89%
Levered Free Cash Flow (ttm)
-83.77M